Table 1.
Baseline characteristics of study population divided into responders (Rpts, n = 34) and non-responders (NRpts, n = 19) based on symptomatic improvement
| Baseline characteristics of study population | n = 53 | Rpts n = 34 | NRpts n = 1 | p value |
|---|---|---|---|---|
| Age (years) | 68 ± 13 | 68 ± 13 | 68 ± 14 | 0.924 |
| Ischemic heart disease (n [%]) | 34 [64%] | 22 [65%] | 12 [63%] | 0.912 |
| Non-ischemic heart disease (n [%]) | 19 [36%] | 12 [35%] | 7 [37%] | 0.912 |
| Atrial fibrillation (n [%]) | 22 [41.5%] | 15 [44.1%] | 7 [36.8%] | 0.614 |
| LV-EF (%) | 27.0 ± 5.9 | 27.8 ± 6.3 | 26.1 ± 4.7 | 0.437 |
| QRS (ms) | 161.2 ± 21.0 | 163.7 ± 23.0 | 158.3 ± 19.2 | 0.422 |
| NYHA III + IV (n [%]) | 42 [79%] | 30 [88%] | 12 [63%] | 0.043 |
| BMI (kg/m2) | 28.2 ± 7.1 | 27.8 ± 7.1 | 29.0 ± 6.9 | 0.581 |
| Hypertension (n [%]) | 36 [67.9%] | 24 [70.6%] | 12 [63.2%] | 0.587 |
| Diabetes (n [%]) | 22 [41.5%] | 14 [41.2%] | 8 [42.1%] | 0.949 |
| Beta blockers (n [%]) | 52 [98.1%] | 34 [100%] | 18 [94.7%] | 0.184 |
| ACE inhibitors (n [%]) | 43 [81.1%] | 29 [85.3%] | 14 [73.7%] | 0.309 |
| ARBs (n [%]) | 10 [18.9%] | 5 [14.7%] | 5 [26.3%] | 0.309 |
| MRAs (n [%]) | 49 [92.5%] | 32 [94.1%] | 17 [89.5%] | 0.548 |
| Diuretics (n [%]) | 52 [98.1%] | 34 [100%] | 18 [94.7%] | 0.184 |
| Amiodarone (n [%]) | 9 [17.0%] | 3 [8.8%] | 3 [15.8%] | 0.866 |
LVEF left-ventricular ejection fraction, QRS duration of QRS in ms, BMI body mass index, ARB angiotensin II receptor blocker. Mean ± SD